{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:13:09Z","timestamp":1782461589057,"version":"3.54.5"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>X-linked hypophosphatemia (XLH) is a rare genetic disorder, for which burosumab treatment may be beneficial. This study evaluated the efficacy, pharmacokinetics, and safety of burosumab in Chinese adults with XLH. In this open-label, multicenter, post-marketing phase 4 study, 18 Chinese adult outpatients with XLH received conventional oral phosphate (30\u00a0mg\/kg\/d in 5 doses) and calcitriol (0.50\u00a0\u03bcg\/d in 2 doses) during a 14-wk run-in period. Patients then received subcutaneous burosumab 1.0\u00a0mg\/kg every 4 wk for 48 wk (12 doses). The main outcome measures were changes from baseline in mean serum phosphate level at the end of burosumab treatment, along with patient-reported outcomes. Sixteen (88.9%) and four (22.2%) patients achieved mean serum phosphate levels &amp;gt;2.5\u00a0mg\/dL at the mid-point and the end of the dose cycle, respectively. The mean (SD) serum phosphate level increased from 1.6 (0.25) mg\/dL at baseline to 2.4 (0.28) mg\/dL at the end of the dose cycle. The mean (SD) change from baseline in serum phosphate level was 50.1% (14.11%) following burosumab treatment. The tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP\/GFR) increased from 1.3 (0.32) mg\/dL at Wk 0 to 2.0 (0.42) mg\/dL at Wk 48. Over 48 wk, patients reported that their worst pain, severity, interference, and stiffness were relieved and Measurement Information System quality of life assessment scores increased. Motor function assessed by the 6-min walking test improved significantly, (72.7% increase from baseline to Wk 48). All treatment-emergent adverse events were mild or moderate; none were serious or serious treatment-related. Burosumab treatment led to sustained correction of serum phosphate levels, enhanced renal phosphate reabsorption (ie, TmP\/GFR improvements), and improved stiffness, pain, and functional exercise capacity. Treatment was well-tolerated without any new safety signals in Chinese patients with XLH.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf097","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T12:11:52Z","timestamp":1753963912000},"source":"Crossref","is-referenced-by-count":1,"title":["Burosumab in Chinese adults with X-linked hypophosphatemia: a phase 4 study"],"prefix":"10.1093","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-1617","authenticated-orcid":false,"given":"Zhenlin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Osteoporosis and Bone Diseases, Shanghai Clinical Research Center of Bone Disease, Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, The Second Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoming","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ji","sequence":"additional","affiliation":[{"name":"Development & Regulatory Division, Kyowa Kirin China Pharmaceutical Co., Ltd. , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Development Division, Kyowa Kirin Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Kuriki","sequence":"additional","affiliation":[{"name":"Development Division, Kyowa Kirin Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5536","authenticated-orcid":false,"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,31]]},"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf097\/63900493\/ziaf097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf097\/63900493\/ziaf097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T12:11:52Z","timestamp":1753963912000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article\/doi\/10.1093\/jbmrpl\/ziaf097\/8219940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf097","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"article-number":"ziaf097"}}